Exercise training and vascular function

Effect of high-intensity interval training on plasma levels of salusin alpha and beta and its relationship with heart rate variability in hypertensive patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150701023002N5

Enrollment

Registered

2025-12-17

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: High-intensity exercise training consists of a 12-week program that includes a 10-minute warm-up, 40 minutes of core training, and a 10-minute cool-down. The progra

Eligibility

Sex/Gender

All

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Middle-age with mild hypertension (90-99 diastolic and 140-159 systolic) Body mass index between 25 and 29 kg/m2 No history of 6 months of regular exercise

Exclusion criteria

Exclusion criteria: Severe blood pressure or grade 3 (more than 110 diastolic and 180 systolic) Cardiac arrhythmia's Cessation of drug use during the study Functional limitation (such as osteoarthritis) Heart failure Chronic gastrointestinal disease (e.g., inflammatory bowel disease) Pregnancy and breastfeeding Secondary blood pressure (including obstructive sleep apnea) Smoking Kidney disease Liver disease Body mass index above 30 kg/m2

Design outcomes

Primary

Measure	Time frame
Salusin alpha. Timepoint: Before and after 12 weeks. Method of measurement: ElISA.;Salusin beta. Timepoint: Before and after 12 weeks. Method of measurement: ELISA.;24 h ambulatory blood pressure. Timepoint: Before and after 12 weeks. Method of measurement: Blood pressure Holter.;VO2 peak. Timepoint: Before and after 12 weeks. Method of measurement: Gas analyzer.;Systolic and diastolic blood pressure. Timepoint: Before and after 12 weeks. Method of measurement: sphygmomanometer.;Arterial stiffness. Timepoint: Before and after 12 weeks. Method of measurement: Ultrasound.;Heart rate Variability. Timepoint: Before and after 12 weeks. Method of measurement: Heart rate holter.;Trimethylamine oxide. Timepoint: Before and after 12 weeks. Method of measurement: HPLC.;Short chain fatty acids. Timepoint: Before and after 12 weeks. Method of measurement: High-performance liquid chromatography (HPLC).	—

Measure

Time frame

Salusin alpha. Timepoint: Before and after 12 weeks. Method of measurement: ElISA.;Salusin beta. Timepoint: Before and after 12 weeks. Method of measurement: ELISA.;24 h ambulatory blood pressure. Timepoint: Before and after 12 weeks. Method of measurement: Blood pressure Holter.;VO2 peak. Timepoint: Before and after 12 weeks. Method of measurement: Gas analyzer.;Systolic and diastolic blood pressure. Timepoint: Before and after 12 weeks. Method of measurement: sphygmomanometer.;Arterial stiffness. Timepoint: Before and after 12 weeks. Method of measurement: Ultrasound.;Heart rate Variability. Timepoint: Before and after 12 weeks. Method of measurement: Heart rate holter.;Trimethylamine oxide. Timepoint: Before and after 12 weeks. Method of measurement: HPLC.;Short chain fatty acids. Timepoint: Before and after 12 weeks. Method of measurement: High-performance liquid chromatography (HPLC).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Ghardashi

University of Tehran

ghardashi.a@ut.ac.ir+98 21 6611 1112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026